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Leaving Nothing Behind*Marc Bosiers, MD
Dendermonde, Belgium
First, I would like to extend my congratulations to Fusaro
et al. (1) on their paper “Drug-Eluting Stents for Revascu-
larization of Infrapopliteal Arteries: Updated Meta-Analysis
of Randomized Trials.”See page 1284The authors address the issue of which devices, currently
at hand, offer the best treatment for a focal below-the-knee
(BTK) lesion. The meta-analysis concludes that for patients
presenting with an infrapopliteal focal disease, primary
stenting with a drug-eluting stent (DES) might be the
primary approach. Treatment of these short lesions with
a DES compared with a bare-metal stent or percutaneous
transluminal angioplasty shows a reduced risk of restenosis,
which is illustrated by the ACHILLES (Comparing
Angioplasty and DES in the Treatment of Subjects With
Ischemic Infrapopliteal Arterial Disease) (2), DESTINY
(Drug Eluting Stents In The Critically Ischemic Lower
Leg) (3), and YUKON-BTK (YUKON-Drug-Eluting
Stent Below The Knee) (4) trials. In these trials, the average
lesion lengths were 26.9 mm, 18.9 mm, and 31 mm, and the
primary patency rates were 80.6%, 85.2%, and 80.6%,
respectively.
In Europe, driven by cost-beneﬁt analyses, we only treat
focal BTK lesions in patients with critical limb ischemia, in
whom patency is not the primary issue. This meta-analysis
shows that primary stenting with a DES also has a positive
impact on the risk of reintervention with an odds ratio of
0.31 (95% conﬁdence interval: 0.18 to 0.54) and on the risk
of amputation with an odds ratio of 0.50 (95% conﬁdence
interval: 0.26 to 0.97).
In line with the “leaving nothing behind” strategy, the
drug-coated balloon might offer a better solution. It has
been proven to work in the superﬁcial femoral artery, but*Editorials published in the JACC: Cardiovascular Interventions reﬂect the views of
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(Drug Eluting Balloon in peripherAl inTErvention For
Below The Knee Angioplasty Evaluation) trial (5) reveals
a 12-month primary patency of a promising 73% in lesions
with an average length of 128 mm. These longer lesions
correspond better to the daily infrapopliteal practice, where
an isolated focal lesion in an otherwise healthy infrapopliteal
artery is the exception. The vast majority of the lesions that
we encounter in critical limb ischemia patients are long and
diffuse. Intervention here with DES treatment makes no
sense. First, there is a higher cost involved, and, second, if
you perform only bail-out stenting with a DES, the long-
term vessel patency is limited by the patency rate of the
treated segment with percutaneous transluminal angioplasty
only.
Probably the drug-eluting absorbable scaffold may be the
best of both worlds. Its scaffolding support without
a permanent metal implant can inhibit acute inﬂammation
after implantation by its local drug release, avoiding the
chronic physical irritation by absorption over time.
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